- Home
- MESO vs PHVS Comparison
MESO vs PHVS Comparison
Compare MESO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- PHVS
- Stock Information
- Founded
- MESO 2004
- PHVS 2015
- Country
- MESO Australia
- PHVS Switzerland
- Employees
- MESO N/A
- PHVS N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- MESO Health Care
- PHVS Health Care
- Exchange
- MESO Nasdaq
- PHVS Nasdaq
- Market Cap
- MESO 1.8B
- PHVS 1.6B
- IPO Year
- MESO N/A
- PHVS 2021
- Fundamental
- Price
- MESO $16.02
- PHVS $24.95
- Analyst Decision
- MESO Strong Buy
- PHVS Buy
- Analyst Count
- MESO 2
- PHVS 7
- Target Price
- MESO $24.00
- PHVS $37.00
- AVG Volume (30 Days)
- MESO 159.9K
- PHVS 282.9K
- Earning Date
- MESO 08-28-2025
- PHVS 11-12-2025
- Dividend Yield
- MESO N/A
- PHVS N/A
- EPS Growth
- MESO N/A
- PHVS N/A
- EPS
- MESO N/A
- PHVS N/A
- Revenue
- MESO $17,198,000.00
- PHVS N/A
- Revenue This Year
- MESO $440.77
- PHVS N/A
- Revenue Next Year
- MESO $110.74
- PHVS N/A
- P/E Ratio
- MESO N/A
- PHVS N/A
- Revenue Growth
- MESO 191.39
- PHVS N/A
- 52 Week Low
- MESO $9.61
- PHVS $11.51
- 52 Week High
- MESO $22.00
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- MESO 52.88
- PHVS 57.14
- Support Level
- MESO $14.32
- PHVS $23.76
- Resistance Level
- MESO $15.61
- PHVS $26.20
- Average True Range (ATR)
- MESO 0.57
- PHVS 1.77
- MACD
- MESO 0.11
- PHVS 0.19
- Stochastic Oscillator
- MESO 87.78
- PHVS 75.19
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.